Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 151 to 160 of 220 total matches.
A Drug Prevention of Anthracycline-Induced Cardiac Toxicity
The Medical Letter on Drugs and Therapeutics • Sep 06, 1991 (Issue 852)
Cerubidine dexrazoxane for cardiotoxicity Cancer chemotherapy Adriamycin daunorubicin doxorubicin ...
Recent studies have caused concern about cardiomyopathy associated with doxorubicin (Adriamycin, and others), daunorubicin (Cerubidine, and others), idarubicin (Idamycin), mitoxantrone (Novantrone), and related anthracycline or anthraquinone anticancer drugs. Dexrazoxane (ADR-529, ICRF-187 - Adria), a piperazine derivative of ethylenediaminetetraacetic acid (EDTA), is now under investigation for prevention of this drug-induced cardiomyopathy.
Irinotecan for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Jan 19, 1997 (Issue 992)
FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
Adrucil CANCER CHEMOTHERAPY ...
Irinotecan hydrochloride (Camptosar - Pharmacia & Upjohn; formerly CPT-11) has been approved by the US Food and Drug Administration for treatment of metastatic colorectal cancer refractory to other drugs including fluorouracil (5-FU; Adrucil and others).
In Brief: A New Indication for Abemaciclib (Verzenio) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
following endocrine therapy and prior chemotherapy in the
metastatic setting.
survival (IDFS ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor
abemaciclib (Verzenio – Lilly) has been approved by
the FDA for use in combination with endocrine therapy
(tamoxifen or an aromatase inhibitor) for adjuvant
treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor
2 (HER2)-negative, node-positive, early breast
cancer at high risk of recurrence.1It was previously
approved for the same indication, but patients were
also required to have a Ki-67 score ≥20%. About
70% of all breast cancers are HR-positive and HER2-negative. Ki-67 is a...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e62-3 doi:10.58347/tml.2023.1673g | Show Introduction Hide Introduction
Pegaspargase for Acute Lymphoblastic Leukemia
The Medical Letter on Drugs and Therapeutics • Mar 17, 1995 (Issue 944)
can tolerate Erwinia asparaginase.
TREATMENT OF ALL — Multidrug chemotherapy now can cure about 70 ...
Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for treatment of acute lymphoblastic leukemia (ALL), the most common malignancy of childhood. The new drug is recommended only for patients who have had allergic reactions to asparaginase. Asparaginase is available commercially as Elspar, which is derived from Escherichia coli. A formulation derived from Erwinia chrysanthemi is available on an investigational basis (Ogden Bioservices,...
Glucarpidase (Voraxaze) for Methotrexate Toxicity
The Medical Letter on Drugs and Therapeutics • Mar 05, 2012 (Issue 1385)
, and in high doses
can cause nephrotoxicity. Patients receiving cancer
chemotherapy with high-dose ...
The FDA has approved glucarpidase (Voraxaze – BTG
International) for treatment of toxic plasma methotrexate
concentrations (>1 micromole per liter) in patients
with delayed methotrexate clearance due to impaired
renal function. Glucarpidase has been available in the
US since 2007 under a compassionate use open-label
treatment protocol (Clinical Trials and Consulting
Services, 1-877-398-9829), which will remain in effect
until the drug becomes commercially available later
this year. There is currently a shortage of IV methotrexate
in the US.
Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia
The Medical Letter on Drugs and Therapeutics • Apr 14, 2014 (Issue 1440)
conditions, who often have difficulty tolerating
chemotherapy, combining rituximab with the alkylating ...
The FDA has approved ibrutinib (eye broo' ti nib;
Imbruvica – Janssen/Pharmacyclics), an oral kinase
inhibitor, for second-line treatment of chronic
lymphocytic leukemia (CLL). It is the first kinase inhibitor
to be approved for CLL. Ibrutinib was approved earlier
for second-line treatment of mantle cell lymphoma, a
rare form of B-cell non-Hodgkins lymphoma.
Omidubicel (Omisirge) for Neutrophil Recovery Following Myeloablative Conditioning Therapy (online only)
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
transplantation, patients
receive myeloablative conditioning therapy with
high-dose chemotherapy ...
The FDA has approved omidubicel-onlv (Omisirge –
Gamida Cell), a nicotinamide-modified, allogeneic
hematopoietic progenitor cell therapy derived from
cord blood, to reduce the time to neutrophil recovery
and the risk of infection in patients ≥12 years old
with hematologic malignancies who will undergo
umbilical cord blood transplantation following
myeloablative conditioning therapy. Hematopoietic
progenitor cell (HPC) umbilical cord products (e.g.,
Allocord, Clevecord, Ducord) have been available in
the US for years for the same indication. Cord blood
banks also supply cord...
Med Lett Drugs Ther. 2023 May 29;65(1677):e93-4 doi:10.58347/tml.2023.1677h | Show Introduction Hide Introduction
Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
to receive osimertinib 80 mg or placebo once daily,
with or without standard adjuvant chemotherapy ...
The FDA has approved osimertinib (Tagrisso –
AstraZeneca), an oral kinase inhibitor, for adjuvant
treatment of non-small cell lung cancer (NSCLC)
after tumor resection in adults who have epidermal
growth factor receptor (EGFR) exon 19 deletions or
exon 21 L858R mutations. Osimertinib is the first
targeted therapy to be approved in the US for this
indication. The drug was previously approved for
first-line treatment of adults with NSCLC with EGFR
exon 19 deletions or exon 21 L858R mutations and for
treatment of EGFR T790M mutation-positive NSCLC
in adults whose disease progressed...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e131-2 doi:10.58347/tml.2023.1682c | Show Introduction Hide Introduction
Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025 (Issue 1720)
evaluating zanidatamab in combination with
chemotherapy, with or without a programmed death
receptor-1 (PD ...
Zanidatamab-hrii (Ziihera – Jazz), a bispecific HER2-directed antibody, has received accelerated approval
from the FDA for treatment of unresectable or metastatic
HER2-positive (IHC 3+) biliary tract cancer in patients
who received prior therapy. Biliary tract cancer includes
gallbladder cancer and intrahepatic and extrahepatic
cholangiocarcinoma. Zanidatamab is the first dual
HER2-targeted therapy to be approved in the US for
this indication. Accelerated approval was based on the
overall response rate and duration of response.
Med Lett Drugs Ther. 2025 Jan 20;67(1720):e16-7 doi:10.58347/tml.2025.1720f | Show Introduction Hide Introduction
Treatment of Clostridium Difficile Diarrhea
The Medical Letter on Drugs and Therapeutics • Oct 20, 1989 (Issue 803)
and Chemotherapy, Houston, Sept 1989, page 107). Vancomycin has been used
more extensively for seriously ill ...
The gram-positive bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea and pseudomembranous colitis (R Fekety in GL Mandell et al, eds, Principles and Practice of Infectious Diseases, 3rd ed, New York:Churchill Livingstone, 1990, page 863). C. difficile colitis usually develops during or soon after antibiotic treatment. Virtually any antimicrobial agent can cause the disorder, but clindamycin, ampicillin and the cephalosporins have been implicated most frequently. Pseudomembranous colitis was recently reported in five patients who had ...